Treprostinil PatchPump - SteadyMed Therapeutics

Drug Profile

Treprostinil PatchPump - SteadyMed Therapeutics

Alternative Names: Trevyent

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SteadyMed Therapeutics
  • Class Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Pulmonary arterial hypertension
  • Clinical Phase Unknown Pulmonary hypertension

Most Recent Events

  • 28 Sep 2017 SteadyMed requested a Type A meeting with the US FDA for Pulmonary arterial hypertension
  • 31 Aug 2017 SteadyMed receives refusal to file letter from the FDA for treprostinil patchpump in Pulmonary arterial hypertension
  • 30 Jun 2017 Preregistration for Pulmonary arterial hypertension in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top